STAFF BOARD
Article
CHAIRMAN
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
MARKETING MANAGER
Margarita Pamplona
EDITORIAL BOARD
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 3, May-June 2017
ORIGINAL
OFF-LABEL USE OF CANNABINOIDS: EFFICACY AND SAFETY
SÁNCHEZ GUNDÍN JULIA, VALERA RUBIO MARTA, GÓMEZ ROMERO LOURDES, GÓMEZ MORENO ISABEL, FLOR GARCÍA AMPARO, BARREDA HERNÁNDEZ DOLORES


Objective: To assess the tolerability, efficacy and safety of delta-9-tetrahydrocan-nabinol (THC)-cannabidiol (CBD) for the treatment of spasticity, painful spasms and/or neuropathic pain not secondary to multiple sclerosis (MS).

Method: A retrospective, descriptive study (02/2012-02/2016) of patients with spasticity, painful spasms and/or neuropathic pain not secondary to MS and treated with THC-CBD.
Variables collected: gender, age, drug therapy prior to THC-CBD, optimal daily dose and concomitant treatment with THC-CBD. Spasticity was assessed by ASHWORTH scale before and after initiation of cannabinoid, and safety by the emergence of adverse drug reactions. We also collected the length of treatment.

Results: Nine patients (62% males, mean age 45 years). Most common diagnosisis was spastic paraplegia related to other diseases (89%) mean of prescribed drugs prior to THC-CBD: 2, most common were: botulinum toxin (78%) baclofen (66%) and tizanidine (44%) mean number of THC-CBD daily sprays: 6.44% of
the treated patients were not prescribed with any other concomitant drug, and the remaining had a mean of two drugs, in addition to THC-CBD.
ASHWORTH scale: three-points at initial treatment, improving to two points following treatment.
Safety: 67% patients experienced adverse reactions leading to the drug with drawal in only one patient (intercurrent digestive infectious process). The most common was somnolence. At the end of the study, 67% patients remained on treatment with THC-CBD after a median of 25 months (5􀀐43) and experienced no loss of efficacy.

Conclusions: THC-CBD could be a treatment option for spasticity, painful spasms and/or neuropathic pain in patients not diagnosed with MS, who have not responded adequately to other conventional anti-spasticity therapies, being a safe and effective treatment choice.

EFFICACY - ENDOCANNABINOIDS - SAFETY - SPASTICITY



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25